Cargando…

Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients

Type 2 diabetes mellitus (T2DM) is a persistent metabolic condition that contributes to the development of cardiovascular diseases. Numerous studies have provided evidence that individuals with T2DM are at a greater risk of developing cardiovascular diseases, typically two to four times more likely...

Descripción completa

Detalles Bibliográficos
Autores principales: Amalia, Muttia, Puteri, Meidi Utami, Saputri, Fadlina Chany, Sauriasari, Rani, Widyantoro, Bambang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381765/
https://www.ncbi.nlm.nih.gov/pubmed/37511848
http://dx.doi.org/10.3390/life13071473
_version_ 1785080524942868480
author Amalia, Muttia
Puteri, Meidi Utami
Saputri, Fadlina Chany
Sauriasari, Rani
Widyantoro, Bambang
author_facet Amalia, Muttia
Puteri, Meidi Utami
Saputri, Fadlina Chany
Sauriasari, Rani
Widyantoro, Bambang
author_sort Amalia, Muttia
collection PubMed
description Type 2 diabetes mellitus (T2DM) is a persistent metabolic condition that contributes to the development of cardiovascular diseases. Numerous studies have provided evidence that individuals with T2DM are at a greater risk of developing cardiovascular diseases, typically two to four times more likely than those without T2DM, mainly due to an increased risk of atherosclerosis. The rupture of an atherosclerotic plaque leading to pathological thrombosis is commonly recognized as a significant factor in advancing cardiovascular diseases caused by TD2M, with platelets inducing the impact of plaque rupture in established atherosclerosis and predisposing to the primary expansion of atherosclerosis. Studies suggest that individuals with T2DM have platelets that display higher baseline activation and reactivity than those without the condition. The expression enhancement of several platelet receptors is known to regulate platelet activation signaling, including platelet glycoprotein-Ib (GPIb). Furthermore, the high expression of platelet GP1b has been reported to increase the risk of platelet adhesion, platelet-leucocyte interaction, and thrombo-inflammatory pathology. However, the study exploring the role of GP1b in promoting platelet activation-induced cardiovascular diseases in T2DM patients is still limited. Therefore, we summarize the important findings regarding pathophysiological continuity between T2DM, platelet GPIb, and atherosclerosis and highlight the potential therapy targeting GPIb as a novel antiplatelet agent for preventing further cardiovascular incidents in TD2M patients.
format Online
Article
Text
id pubmed-10381765
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103817652023-07-29 Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients Amalia, Muttia Puteri, Meidi Utami Saputri, Fadlina Chany Sauriasari, Rani Widyantoro, Bambang Life (Basel) Review Type 2 diabetes mellitus (T2DM) is a persistent metabolic condition that contributes to the development of cardiovascular diseases. Numerous studies have provided evidence that individuals with T2DM are at a greater risk of developing cardiovascular diseases, typically two to four times more likely than those without T2DM, mainly due to an increased risk of atherosclerosis. The rupture of an atherosclerotic plaque leading to pathological thrombosis is commonly recognized as a significant factor in advancing cardiovascular diseases caused by TD2M, with platelets inducing the impact of plaque rupture in established atherosclerosis and predisposing to the primary expansion of atherosclerosis. Studies suggest that individuals with T2DM have platelets that display higher baseline activation and reactivity than those without the condition. The expression enhancement of several platelet receptors is known to regulate platelet activation signaling, including platelet glycoprotein-Ib (GPIb). Furthermore, the high expression of platelet GP1b has been reported to increase the risk of platelet adhesion, platelet-leucocyte interaction, and thrombo-inflammatory pathology. However, the study exploring the role of GP1b in promoting platelet activation-induced cardiovascular diseases in T2DM patients is still limited. Therefore, we summarize the important findings regarding pathophysiological continuity between T2DM, platelet GPIb, and atherosclerosis and highlight the potential therapy targeting GPIb as a novel antiplatelet agent for preventing further cardiovascular incidents in TD2M patients. MDPI 2023-06-29 /pmc/articles/PMC10381765/ /pubmed/37511848 http://dx.doi.org/10.3390/life13071473 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Amalia, Muttia
Puteri, Meidi Utami
Saputri, Fadlina Chany
Sauriasari, Rani
Widyantoro, Bambang
Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients
title Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients
title_full Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients
title_fullStr Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients
title_full_unstemmed Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients
title_short Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients
title_sort platelet glycoprotein-ib (gpib) may serve as a bridge between type 2 diabetes mellitus (t2dm) and atherosclerosis, making it a potential target for antiplatelet agents in t2dm patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381765/
https://www.ncbi.nlm.nih.gov/pubmed/37511848
http://dx.doi.org/10.3390/life13071473
work_keys_str_mv AT amaliamuttia plateletglycoproteinibgpibmayserveasabridgebetweentype2diabetesmellitust2dmandatherosclerosismakingitapotentialtargetforantiplateletagentsint2dmpatients
AT puterimeidiutami plateletglycoproteinibgpibmayserveasabridgebetweentype2diabetesmellitust2dmandatherosclerosismakingitapotentialtargetforantiplateletagentsint2dmpatients
AT saputrifadlinachany plateletglycoproteinibgpibmayserveasabridgebetweentype2diabetesmellitust2dmandatherosclerosismakingitapotentialtargetforantiplateletagentsint2dmpatients
AT sauriasarirani plateletglycoproteinibgpibmayserveasabridgebetweentype2diabetesmellitust2dmandatherosclerosismakingitapotentialtargetforantiplateletagentsint2dmpatients
AT widyantorobambang plateletglycoproteinibgpibmayserveasabridgebetweentype2diabetesmellitust2dmandatherosclerosismakingitapotentialtargetforantiplateletagentsint2dmpatients